Changes of serum MG7-Ag and CA125 levels before and after chemotherapy in patients with advanced cervical cancer and their relationships with the curative effect
10.3760/cma.j.issn.1673-422X.2018.11.008
- VernacularTitle:血清MG7-Ag、 CA125在晚期宫颈癌患者化疗前后的水平变化及其与疗效的关系
- Author:
Nanyou LUO
1
Author Information
1. 642150,四川省隆昌市人民医院检验科
- Keywords:
Uterine cervical neoplasms;
Drug therapy;
Treatment outcome;
CA-125 antigen;
Gastric cancer associated antigen MG7
- From:
Journal of International Oncology
2018;45(11):675-680
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the changes of serum gastric cancer associated antigen MG7 (MG7-Ag),carbohydrate antigen 125 (CA125) levels before and after chemotherapy in patients with advanced cervical cancer and their relationships with the curative effect.Methods A total of 150 advanced cervical cancer patients with paclitaxel combined with cisplatin treatment were selected from June 2014 to June 2017 in our hospital,and 150 cases of healthy persons were selected at the same time.The serum MG7-Ag and CA125 levels of all persons were detected.The differences of MG7-Ag and CA125 levels between healthy persons and advanced cervical cancer patients were analyzed.And the changes of MG7-Ag,CA125 levels before and after chemotherapy and the relationships between the MG7-Ag,CA125 levels and the curative effect of chemotherapy were analyzed.Results The serum MG7-Ag and CA125 levels in the patients with advanced cervical cancer were significantly higher than those in the healthy persons [(15.36 ±2.23) U/ml vs.(2.42 ±0.31) U/ml,(275.42 ± 30.52) U/ml vs.(1 1.89 ± 1.77) U/ml],and the differences were statistically significant (t =26.215,P ＜0.001;t =82.243,P ＜ 0.001).After chemotherapy for 150 patients with advanced cervical cancer,the complete remission (CR) was 5 cases (3.33％),the partial remission (PR) was 58 cases (38.67％),the stable disease (SD) was 60 cases (40.00％),and the progression disease (PD) was 27 cases (18.00％).The MG7-Ag and CA125 levels after chemotherapy in the patients with CR and PR were decreased significantly than those before chemotherapy [(7.12 ± 1.22) U/ml vs.(15.12 ± 3.32) U/ml,(180.34±22.42) U/mlvs.(274.21 ±30.82) U/ml,(9.22 ±1.77) U/mlvs.(15.52 ±3.53) U/ml,(206.75 ±23.02) U/ml vs.(276.12 ±30.92) U/ml],and the differences were statistically significant (t =5.057,P=0.001;t=12.150,P＜0.001,t =5.507,P＜0.001;t =13.705,P＜0.001).The MG7-Ag and CA125 levels after chemotherapy in the patients with PD were increased significantly than those before chemotherapy [(24.21 ± 3.64) U/ml vs.(15.56 ± 3.87) U/ml,(376.64 ± 45.12) U/ml vs.(280.75 ± 31.88) U/ml],and the differences were statistically significant (t =8.460,P ＜0.001;t =9.019,P ＜0.001).The MG7-Ag,CA125 levels after chemotherapy in the patients with SD were increased than those before chemotherapy [(16.01±2.37) U/mlvs.(15.67±3.55) U/ml,(285.26±37.34) U/mlvs.(277.04±31.73) U/ml],but the differences were not statistically significant (t =0.617,P =0.538;t =1.299,P =0.196).The results of receiver operatingcharacteristic (ROC) curve analysis showed that,in the aspect of sensitivity,specificity and accuracy of chemotherapy effect evaluation for cervical cancer,MG7-Ag decline percentage with ＞ 25％ as the critical value were 82.54％,82.76％,82.67％,CA125 decline percentage with ＞ 18％ as the critical value were 85.71％,86.21％,86.00％,and the combination of the two were 96.83％,97.70％,97.33 ％.The combination of the two were significantly higher than that of the two alone,and the differences were statistically significant (x2 =6.948,P =0.008;x2 =11.018,P =0.001;x2 =17.926,P ＜0.001;x2 =4.881,P =0.027;x2 =7.768 P =0.005;x2 =12.611,P ＜ O.001).Conclusion The serum MG7-Ag and CA125 levels in patients with advanced cervical cancer are higher than those in healthy persons.The MG7-Ag and CA125 levels of patients with CR and PR are decreased after chemotherapy,and their changes of serum levels can be used as the important indexes for evaluating the efficacy of chemotherapy.The combined detection of them has the better evaluation efficiency,and it is worth for further clinical promotion.
